---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018297"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:13:48.177912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M

## Summary
- Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.
- Net loss $26.0M ($0.10 per share) vs $12.9M ($0.05) in Q1 2021, driven by lower collaboration revenue.
- Cash and investments $233.0M at March 31, 2022; Tyvaso DPI PDUFA action date expected May 2022.
- Collaborations & services revenue $2.2M, down $7.2M due to completion of R&D services for United Therapeutics.
- Deferred revenue from commercial supply agreement with United Therapeutics increased to $25.7M.

## SEC filing metadata
- accession: 0001564590-22-018297
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/0001564590-22-018297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/mnkd-8k_20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018297
- JSON: https://secwatch.observer/filing/0001564590-22-018297.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.